所有图片(1)

文件

Y0001574

美沙拉嗪

Name: 美沙拉嗪
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

所有图片(1)

别名:

5-氨基水杨酸, 5-AS, 5-氨基-2-羟基苯甲酸, 氨水杨酸

线性分子式:

H₂NC₆H₃-2-(OH)CO₂H

CAS号:

89-57-6

分子量:

153.14

Beilstein:

2090421

MDL编号:

MFCD00007877

PubChem化学物质编号:

329831489

NACRES:

NA.24

等级

pharmaceutical primary standard

API类

mesalazine, mesalamine

制造商/商品名称

EDQM

mp

275-280 °C (dec.) (lit.)

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

Nc1ccc(O)c(c1)C(O)=O

InChI

1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)

InChI key

KBOPZPXVLCULAV-UHFFFAOYSA-N

基因信息

human ... ALOX5(240) , PPARG(5468) , PTGS1(5742) , PTGS2(5743)

正在寻找类似产品? Visit 产品对比指南

一般描述

本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持，请访问现行药典网站。

应用

5-氨基水杨酸是适用于ELISA分析的过氧化物酶底物。这一底物产生可溶性的棕色终产物，可在450nm处通过分光光度法读取。使用3 N NaOH可终止反应并在550 nm处读取结果。

包装

本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。

其他说明

可能适用相应的销售限制。

PHR1060

氨水杨酸, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1148

警示用语：

Warning

危险声明

H315 - H317 - H319 - H335

预防措施声明

P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338

危险分类

Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

No data available

闪点(°C)

No data available

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

如何查找产品货号

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503

货号

25G

包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务寻求帮助

如何查找COA批号

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。
如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。
如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

Mesalazine in inflammatory bowel disease: a trendy topic once again?

Marietta Iacucci et al.

Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 24(2), 127-133 (2010-02-13)

5-aminosalicylic acid (5-ASA) preparations (eg, mesalazine, mesalamine) are well-established preparations used in the management of inflammatory bowel disease. These drugs are most useful for the treatment of mild to moderate flares of ulcerative colitis and, especially, for maintenance of remission.

Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease.

A H Steinhart et al.

Alimentary pharmacology & therapeutics, 25(12), 1389-1399 (2007-06-02)

To evaluate the effectiveness of pH 6-/pH 7-dependent and controlled-release mesalazines in maintaining medically and surgically induced Crohn's disease remission. A systematic search identified 13 randomized controlled trials (RCTs). The rate of symptomatic relapse (Crohn's disease activity index >150, or

Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.

David T Rubin et al.

Inflammatory bowel diseases, 14(2), 265-274 (2007-10-13)

A roundtable consensus meeting was held to consolidate current knowledge on the etiology of colorectal cancer in patients with inflammatory bowel disease and to review current strategies, both diagnostic and preventive, specifically addressing the role of 5-aminosalicylic acid. Specific topics

Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials.

Jeffrey B Raskin et al.

Gastroenterology, 147(4), 793-802 (2014-07-20)

No therapy has been proven to prevent the recurrence of diverticulitis. Mesalamine has shown efficacy in preventing relapse in inflammatory bowel disease, and there is preliminary evidence that it might be effective for diverticular disease. We investigated the efficacy of

First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses.

Max Karner et al.

The American journal of gastroenterology, 109(7), 1041-1051 (2014-05-07)

Phosphatidylcholine is a key component of the mucosal barrier. Treatment with modified release phosphatidylcholine aims to improve the impaired barrier function. The primary objective is to evaluate the efficacy of LT-02, a newly designed modified release phosphatidylcholine formula, in a

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件